CELLCENTRIC LIMITED
BioTech/Drugs - Uttlesford, , UK
CELLCENTRIC LIMITED Employees
CELLCENTRIC LIMITED Senior Management
CELLCENTRIC LIMITED Details
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally.p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers.CellCentric's pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.
CELLCENTRIC LIMITED Technologies
Email Providers
Outlook
Load Balancers
Nginx
Hosting
DigitalOcean
Analytics and Tracking
Google Analytics
Other
Mobile Friendly